Kynam Capital Management, LP

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Kynam Capital Management, LP reported 21 stock positions worth $898.9 million. Its top holding was Natera (NTRA) at 20.3% of the portfolio, followed by Syndax Pharmaceuticals (SNDX, 15.0%) and Celldex Therapeutics (CLDX, 13.5%). Compared with Q4 2023, it opened 1 new position, sold out of 3, added to 5 and reduced 8. The biggest buy was Dynavax Technologies (DVAX, shares +180%) and the biggest sale an exit from Immunogen (IMGN).

Most Recent 13F
Q2 2026
Location
PRINCETON, NJ
CIK
0001907884
Portfolio Value
$898.9M (Q1 2024)
SEC Filing
0001085146-24-002547 ↗ filed May 15, 2024

Holdings Value

0$500.0M$1.0B$1.5B$2.0B Q1 2024: $898.9M $898.9M Q1 2024 Q2 2024: $955.2M Q2 2024 Q3 2024: $1.3B Q3 2024 Q4 2024: $1.5B Q4 2024 Q1 2025: $1.2B Q1 2025 Q2 2025: $928.8M Q2 2025 Q3 2025: $1.3B Q3 2025 Q4 2025: $1.5B Q4 2025 Q1 2026: $1.6B Q1 2026 Q2 2026: $1.8B Q2 2026

Holdings 21 stocks · $898.9M
NTRA Natera Inc. 20.35% 2,000,000 $182.9M Reduce -16.7%
SNDX Syndax Pharmaceuticals Inc. 14.99% 5,660,000 $134.7M No change
CLDX Celldex Therapeutics Inc. 13.54% 2,900,000 $121.7M Reduce -3.5%
VERA Vera Therapeutics Inc. 7.32% 1,526,787 $65.8M Reduce -58.2%
COGT Cogent Biosciences Inc. 6.35% 8,500,000 $57.1M Add +45.2%
DVAX Dynavax Technologies Corp. 5.85% 4,239,780 $52.6M Add +180.0%
PCVX Vaxcyte Inc. 5.66% 745,000 $50.9M Reduce -25.7%
LQDA Liquidia Corp. 3.69% 2,248,324 $33.2M Reduce -16.7%
BCRX Biocryst Pharmaceuticals Inc. 3.69% 6,527,491 $33.2M Add +41.9%
PTGX Protagonist Therapeutics Inc. 3.68% 1,144,242 $33.1M Reduce -42.9%
TSVT 2SEVENTY Bio Inc. 3.54% 5,953,825 $31.9M No change
WVE Wave Life Sciences Ltd. 2.70% 3,932,082 $24.3M No change
TVTX Travere Therapeutics Inc. 1.72% 2,000,000 $15.4M No change
IRWD Ironwood Pharmaceuticals Inc. 1.57% 1,625,000 $14.2M New
STRO Sutro Biopharma Inc. Com SHS 1.26% 2,001,727 $11.3M No change
AMARIN CORP PLC 1.19% 12,022,957 $10.7M No change
TYRA Tyra Biosciences Inc. 0.94% 515,190 $8.4M Add +51.4%
BNR Burning Rock Biotech Ltd.-ADR 0.78% 9,640,914 $7.0M Add +10.9%
CRBU Caribou Biosciences Inc. 0.61% 1,068,527 $5.5M No change
SLRN Acelyrin Inc. 0.30% 396,379 $2.7M Reduce -67.0%
VRDN Viridian Therapeutics Inc. 0.26% 133,877 $2.3M Reduce -78.0%

Options reported separately and not counted above: VRTX puts ($41.8M), CORT puts ($14.8M).

Portfolio Sells Q4 2023 → Q1 2024
IMGN Immunogen Inc. Sold out 0.00% −4.77
MOR Morphosys AG ADR Sold out 0.00% −4.74
PTGX Protagonist Therapeutics Inc. Reduce -42.9% 3.68% −1.52
PCVX Vaxcyte Inc. Reduce -25.7% 5.66% −1.46
VRDN Viridian Therapeutics Inc. Reduce -78.0% 0.26% −1.24
SLRN Acelyrin Inc. Reduce -67.0% 0.30% −0.72
CNTA Centessa Pharmaceuticals Ltd. Sold out 0.00% −0.40
LQDA Liquidia Corp. Reduce -16.7% 3.69% +0.02
CLDX Celldex Therapeutics Inc. Reduce -3.5% 13.54% +0.05
VERA Vera Therapeutics Inc. Reduce -58.2% 7.32% +0.97
NTRA Natera Inc. Reduce -16.7% 20.35% +3.33

Portfolio Buys Q4 2023 → Q1 2024
DVAX Dynavax Technologies Corp. Add +180.0% 5.85% +3.46
COGT Cogent Biosciences Inc. Add +45.2% 6.35% +2.46
IRWD Ironwood Pharmaceuticals Inc. New 1.57% +1.57
BCRX Biocryst Pharmaceuticals Inc. Add +41.9% 3.69% +0.57
TYRA Tyra Biosciences Inc. Add +51.4% 0.94% +0.41
BNR Burning Rock Biotech Ltd.-ADR Add +10.9% 0.78% −0.13

Options Activity Q4 2023 → Q1 2024
VRTX Vertex Pharmaceuticals Inc. put New 100,000 $41.8M

Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 32$1.8BCLDX, SNDX, PCVX, COGT, VERA
Q1 2026 36$1.6BSNDX, CLDX, PCVX, COGT, VERA
Q4 2025 35$1.5BCOGT, VERA, SNDX, CLDX, PCVX
Q3 2025 35$1.3BCLDX, SNDX, VERA, COGT, PCVX
Q2 2025 31$928.8MCLDX, PCVX, VERA, SNDX, BCRX
Q1 2025 31$1.2BNTRA, PCVX, CLDX, SNDX, BCRX
Q4 2024 29$1.5BNTRA, PCVX, CLDX, SNDX, DVAX
Q3 2024 24$1.3BNTRA, PCVX, CLDX, SNDX, COGT
Q2 2024 22$955.2MNTRA, CLDX, SNDX, DVAX, COGT
Q1 2024 21$898.9MNTRA, SNDX, CLDX, VERA, COGT